Drugs / CT-P66
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05224856 | Apr → Nov 2022 | COVID-19 | Celltrion | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-P66 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05224856 ↗ |
| Modality | Monoclonal antibody | “CT-P63 and CT-P66 are monoclonal antibodies targeted against SARS-CoV-2 spike receptor binding domain as a treatment for COVID-19 infection.” NCT05224856 ↗ |